The design of compounds with desirable properties - The anti-HIV case study

被引:2
|
作者
Novak, Jurica [1 ,2 ,3 ]
Pathak, Prateek [4 ]
Grishina, Maria A. [4 ]
Potemkin, Vladimir A. [4 ]
机构
[1] Univ Rijeka, Dept Biotechnol, Rijeka 51000, Croatia
[2] Univ Rijeka, Ctr Artificial Intelligence & Cybersecur, Rijeka, Croatia
[3] South Ural State Univ, Sci & Educ Ctr Biomed Technol, Higher Med & Biol Sch, Chelyabinsk, Russia
[4] South Ural State Univ, Higher Med & Biol Sch, Lab Computat Modelling Drugs, Chelyabinsk 454080, Russia
关键词
3CLpro; cytotoxicity; drug repurposing; HIV-1; protease; QSAR; PROTEASE INHIBITORS; DRUG-RESISTANCE; PREDICTION; SYSTEM;
D O I
10.1002/jcc.27061
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Efficacy and safety are among the most desirable characteristics of an ideal drug. The tremendous increase in computing power and the entry of artificial intelligence into the field of computational drug design are accelerating the process of identifying, developing, and optimizing potential drugs. Here, we present novel approach to design new molecules with desired properties. We combined various neural networks and linear regression algorithms to build models for cytotoxicity and anti-HIV activity based on Continual Molecular Interior analysis (CoMIn) and Cinderella's Shoe (CiS) derived molecular descriptors. After validating the reliability of the models, a genetic algorithm was coupled with the Des-Pot Grid algorithm to generate new molecules from a predefined pool of molecular fragments and predict their bioactivity and cytotoxicity. This combination led to the proposal of 16 hit molecules with high anti-HIV activity and low cytotoxicity. The anti-SARS-CoV-2 activity of the hits was predicted.
引用
收藏
页码:1016 / 1030
页数:15
相关论文
共 50 条
  • [1] Design, synthesis, anti-HIV and cytotoxicity of novel heterocyclic compounds
    Selvam, Periyasamy
    Murugesh, Narayanan
    Chandramohan, Markandavel
    De Clercq, Erik
    Pannecouque, Christophe
    ANTIVIRAL RESEARCH, 2007, 74 (03) : A51 - A51
  • [3] Anti-HIV design - Preface
    Parang, K
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (22)
  • [4] Anti-HIV design - Preface
    Parang, K
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (08)
  • [5] A density functional study of flavonoid compounds with anti-HIV activity
    Lameira, J.
    Alves, C. N.
    Moliner, V.
    Silla, E.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2006, 41 (05) : 616 - 623
  • [6] Anti-HIV drug design and therapy
    Ross, TM
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (32) : 4003 - 4003
  • [8] Glycolysis Inhibitors as Potential Anti-HIV Compounds
    Songok, Elijah
    Nzau, Benjamin
    Wainberg, Mark
    Plummer, Frank
    Mpoke, Solomon
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A206 - A207
  • [9] A RAPID SCREENING METHOD FOR ANTI-HIV COMPOUNDS
    GALPIN, SA
    JEFFRIES, DJ
    KINCHINGTON, D
    ANTIVIRAL RESEARCH, 1988, 9 (1-2) : 117 - 117
  • [10] Studies directed toward anti-HIV compounds
    Gurjar, MK
    Lalitha, SVS
    PURE AND APPLIED CHEMISTRY, 1998, 70 (02) : 303 - 306